Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial

Waning of neutralizing titres along with decline of protection efficacy after the second dose of COVID-19 vaccines was observed, including China-made inactivated vaccines. Efficacy of a heterologous boosting using one dose of a recombinant SARS-CoV-2 fusion protein vaccine (V-01) in inactivated vacc...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xuan-Yi, Mahmood, Syed Faisal, Jin, Fang, Cheah, Wee Kooi, Ahmad, Muhammad, Sohail, Mian Amjad, Ahmad, Waheed, Suppan, Vijaya K., Sayeed, Muneeba Ahsan, Luxmi, Shobha, Teo, Aik-Howe, Lee, Li Yuan, Qi, Yang-Yang, Pei, Rong-Juan, Deng, Wei, Xu, Zhong-Hui, Yang, Jia-Ming, Zhang, Yan, Guan, Wu-Xiang, Yu, Xiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Coronaviruses
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9347473/
https://www.ncbi.nlm.nih.gov/pubmed/35686572
http://dx.doi.org/10.1080/22221751.2022.2088406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9347473/
https://www.ncbi.nlm.nih.gov/pubmed/35686572
http://dx.doi.org/10.1080/22221751.2022.2088406

Ejemplares similares